TLX 112
Alternative Names: TLX-112Latest Information Update: 26 Dec 2022
Price :
$50 *
At a glance
- Originator Tulex Pharmaceuticals
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 26 Dec 2022 No development reported - Preregistration for Cardiovascular disorders in USA (unspecified route)
- 15 Oct 2020 TLX 112 is available for licensing as of 15 Oct 2020. https://www.tulexpharm.com/
- 15 Oct 2020 Preregistration for Cardiovascular disorders in USA (Tulex Pharmaceuticals pipeline, October 2020)